We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.15 | -1.62% | 9.10 | 8.70 | 9.50 | 9.25 | 9.10 | 9.25 | 321,812 | 14:04:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.05 | 84.43M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2019 14:03 | For someone who thinks he knows it all I see Inanaco still has very little to say today. Shame really, it just clogs up the drains. ATB | oldnotwise | |
24/4/2019 14:01 | ineptico.... i think i can confirm that Berm was indeed arguing with you, not himself. I can also confirm that he's caught you lying YET AGAIN. Now please slither back under your rock. | tosh123 | |
24/4/2019 14:00 | Inanaco, The new recruits were not brought in as dedicated staff for the BioNTech collaboration, you suggested they were and they weren't. Right now I hope and expect they're up to their eyeballs with the SCIB1 and Modi1 trials. I agree, Modi3 was interesting and part of a more wider reaching project but it wasn't an extension at all of the BioNTech collaboration as you claimed. | bermudashorts | |
24/4/2019 13:54 | Bermuda like i said you did not read the post ... I cannot help you with this, you are very experienced at taking words out of context then creating an argument with yourself, so it appears like an argument with me. I have got used to it now ,,,, I just highlight your exploits .. in Neon lights .. | inanaco | |
24/4/2019 13:54 | Caught lying YET AGAIN.... dear oh dear... what a surprise ! | tosh123 | |
24/4/2019 13:50 | 2/ "Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics and I am very excited to add such an experienced scientist to the team." as we are speculating ....... on a deal for TCR etc .. 1/ what ever Modi3 is ... it's pretty universal Project Blueprint was devised to investigate the potential of cancer vaccines, based on treatment with Modi-3, a product generated from Scancell's Moditope® platform, alongside vaccines targeting new mutations within individual patient tumours, for the treatment of virtually all cancers. speculation should be what is it .. ? | inanaco | |
24/4/2019 13:49 | ..........but that's not my opinion, it's based on RNS announcements directly from Scancell. | bermudashorts | |
24/4/2019 13:46 | Just go back to your hovel. Your rubbish will just clutter an otherwise informative and open BB. I dont think that anyone wants you here, so for once in your life, do the honourable thing and disappear back under your rock. | tosh123 | |
24/4/2019 13:42 | and as per usual Bermuda .. you never read the post .. but fly off the handle in an uncontrolled manner leading to a slap down """ the only thing you can speculate on is evidence"" thank you for speculating with your opinion .. | inanaco | |
24/4/2019 13:38 | Inanaco, 1) The BioNTech collaboration was not in any shape or form extended by Modi3/the Grand Challenge pitch. That was a completely different and separate enterprise. 2) Dedicated staff have not been employed. | bermudashorts | |
24/4/2019 13:35 | Unfortunately Tosh .. your displays of late which might go down well in some sort of male ritual dance to female chimps, is not very inspiring to this BB .. however i will not be the one to deprive you of your exploits which are available on Red Tube | inanaco | |
24/4/2019 13:33 | torquayfan - no offence taken at all. | gooosed | |
24/4/2019 13:31 | Gooosed, you are one of the few posters who regularly post useful and relevant links and information and I'm sure I'm not alone in finding them anything but worthless. Inanaco, your comment regarding goooosed's post and the need for evidence is somewhat ironic in light of the lack of evidence to support the incorrect assumptions in your 13.06. | bermudashorts | |
24/4/2019 13:19 | Twould appear that theres no such luck, as the resident plonker continues to post in a manner that try's to stifle debate and discredit anyone who has a view other than his uneducated waffle. The most despicable, uneducated low life that i have ever had the misfortune to encounter. | tosh123 | |
24/4/2019 13:03 | I notice that the village idiot has been roused from his sleep by " an outbreak of honesty "... He hates it when people debate anything other than what suits his own agenda. Lets hope the clown disappears as quickly as he appeared... he's a menace. | tosh123 | |
24/4/2019 12:22 | Gooosed. Re. the issue of data being needed to help the SP, as raised by ONW - I was interested in the point and the part of your reply 21645 which dealt with it. I thought this might be a useful reminder on LSE - I alluded to ONW's point and copied the relevant part of your reply on that 'data' point re BioNTech . . I hope that caused you no offence - that is, in not posting the whole of 21645 but the whole part relevant to the 'BioNTech data' topic. Was that OK with you ? If not, I shall not do so again. That's it. ATB | torquayfan | |
24/4/2019 08:09 | Gooosed, good point, let's hope for some fruit from the Biontech situation, but I'm not inhaling deeply. I take your points. Fingers crossed..... :-/ ATB | oldnotwise | |
23/4/2019 23:02 | That DATA may first appear in the form of the pre-clinical type via the BioNTech collaboration. A little over 9 weeks until the end of the initial collaboration period. If not then it's a depressingly long haul with Holloway at the helm hawking his wares (CV included) and on it goes. | gooosed | |
23/4/2019 22:07 | If anyone really thinks that the average PI investing in Bios understands the underlying technology (in almost any of the companies on AIM) I'd be amazed. Surely that's the whole point of these sort of "one to ones", it's about drawing in new blood to the investor base, who can then happily subscribe to the next fundraiser should it be another call to existing holders. Any deep discounted new shares are unlikley to be available to the sort of people attending the Proactive presentations, that paper will be the domain of the II who'll likely have a greater level of indicative info (not hard evidence - that would be unthinkable wouldn't it) when the big calls (prior to substansive announcements) are made. So the little guys get the snippets, the Big boys get the meat. Am I being too cynical? Answers on a postcard please to....... :-) Maybe that's why I was thinking about another small Placing to keep the lights on as the days grow shorter later on, with a much bigger fundraiser when we really have something to announce, I'm not sure the short term commencement of the US Trial will create enough momentum to get us to a level where good money can be easily raised. I'm sure that'l come but for that we need DATA DATA DATA..... AIMO ATB | oldnotwise | |
23/4/2019 21:20 | Bermuda 21640 - exactly. A PI newly coming to this science ain't gonna understand enough to invest after 20 minutes and a few questions. Just formation dancing in PR terms. Unless . . | torquayfan | |
23/4/2019 21:05 | Gazza. Yes RNS is the platform for 'news'. News events have their own timing and not necessarily fitting into an AGM / ProA etc. Thursday's "Event' is a PR trundle but IF news of any kind is around, CH will obviously be talking about it. Some updates may emerge. Your comment about the fundraise - Scancell have always acted early. Maybe today / tomorrow. Hope you are right about an share price 10p again. For some balance, it's also possible that some sort of 'deal' might be around . . . but I'm not holding my breath at all. Soon we'll know. | torquayfan | |
23/4/2019 17:21 | Berm, and there was me being relatively positive when I suppose I wasn't really.... LOL. I must agree, but it was simply the way the flyer was worded.... Given the general concensus re funding... We'll find out anyway, at some point, eventually! AIMO ATB | oldnotwise | |
23/4/2019 16:24 | Not sure that a presentation to a handful of PIs which isn't even recorded for wider distribution is quite going to cut it in terms of drumming up support for the sort of funding Scancell need. | bermudashorts | |
23/4/2019 16:16 | Gazza, Maybe :-) ATB | oldnotwise |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions